

David H Birnie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/715285/publications.pdf>

Version: 2024-02-01

195
papers

10,828
citations

50276

46
h-index

32842

100
g-index

195
all docs

195
docs citations

195
times ranked

7856
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex Differences in Implantation and Outcomes of Cardiac Resynchronization Therapy in Real-World Settings: A Systematic Review of Cohort Studies. <i>CJC Open</i> , 2022, 4, 75-84.	1.5	9
2	Integrating sex and gender in studies of cardiac resynchronization therapy: a systematic review. <i>ESC Heart Failure</i> , 2022, 9, 420-427.	3.1	12
3	Metabolic activity of the left and right atria are differentially altered in patients with atrial fibrillation and LV dysfunction. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2824-2836.	2.1	2
4	When to Suspect and Investigate Cardiac Sarcoidosis. <i>Canadian Journal of Cardiology</i> , 2022, 38, 549-551.	1.7	2
5	Should they stay, or should they go: do we need to remove the old cardiac implantable electronic device if a new system is required on the contralateral side?. <i>Heart Rhythm O2</i> , 2022, 3, 169-175.	1.7	1
6	How to risk-stratify cardiac sarcoidosis patients with normal or near-normal ventricular function?. <i>Heart Rhythm</i> , 2022, 19, 361-362.	0.7	0
7	Cardiac sarcoidosis. , 2022, , 142-159.		1
8	Outcomes of a comprehensive strategy during repeat atrial fibrillation ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 391-399.	1.3	6
9	Augmented wide area circumferential catheter ablation for reduction of atrial fibrillation recurrence (AWARE) trial: Design and rationale. <i>American Heart Journal</i> , 2022, 248, 1-12.	2.7	4
10	Negative Association with Smoking History and Clinically Manifest Cardiac Sarcoidosis; a case-control study.. <i>CJC Open</i> , 2022, , .	1.5	1
11	Regarding "Waxing and Waning Presentation of Isolated Cardiac Sarcoidosis on Sequential ¹⁸ F-FDG PET Exams". <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 292-292.	0.8	0
12	A randomized, controlled comparison of electrical versus pharmacological cardioversion for emergency department patients with acute atrial flutter. <i>Canadian Journal of Emergency Medicine</i> , 2021, 23, 314-324.	1.1	5
13	Differences in Healthcare Use Between Patients With Persistent and Paroxysmal Atrial Fibrillation Undergoing Catheter-Based Atrial Fibrillation Ablation: A Population-Based Cohort Study From Ontario, Canada. <i>Journal of the American Heart Association</i> , 2021, 10, e016071.	3.7	4
14	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	4.8	14
15	Cardiac Sarcoidosis and Giant Cell Myocarditis: Actually, 2 Ends of the Same Disease?. <i>Journal of the American Heart Association</i> , 2021, 10, e020542.	3.7	6
16	High-power, short-duration atrial fibrillation ablation compared with a conventional approach: Outcomes and reconnection patterns. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1219-1228.	1.7	19
17	Ten Questions Cardiologists Should Be Able to Answer About Cardiac Sarcoidosis: Case-Based Approach and Contemporary Review. <i>CJC Open</i> , 2021, 3, 532-548.	1.5	7
18	Cover Image, Volume 32, Issue 5. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, i.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Prevalence of Left Atrial Appendage Thrombus in Patients Anticoagulated With Direct Oral Anticoagulants: Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, 658-665.	1.5	6
20	Epidemiology of cardiac implantable electronic device infections: incidence and risk factors. <i>Europace</i> , 2021, 23, iv3-iv10.	1.7	38
21	COUNTERPOINT: Should Isolated Cardiac Sarcoidosis Be Considered a Significant Manifestation of Sarcoidosis? No. <i>Chest</i> , 2021, 160, 38-42.	0.8	11
22	Sex differences in CRT device implantation rates, efficacy, and complications following implantation: protocol for a systematic review and meta-analysis of cohort studies. <i>Systematic Reviews</i> , 2021, 10, 210.	5.3	1
23	Rebuttal From Drs Birnie, Nery, and Beanlands. <i>Chest</i> , 2021, 160, 43-44.	0.8	1
24	Management of ventricular tachycardia in patients with cardiac sarcoidosis. <i>Heart Rhythm O2</i> , 2021, 2, 412-422.	1.7	8
25	Adverse Events Associated With Electrical Cardioversion in Patients With Acute Atrial Fibrillation and Atrial Flutter. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1775-1782.	1.7	9
26	Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review. <i>Journal of the American Heart Association</i> , 2021, 10, e021183.	3.7	35
27	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	1.7	7
28	Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). <i>Journal of Translational Medicine</i> , 2021, 19, 460.	4.4	23
29	Bang for the buck: the importance of modifiable factors for electrical cardioversion of atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 721-721.	2.2	3
30	A new electrocardiographic definition of left bundle branch block (LBBB) in patients after transcatheter aortic valve replacement (TAVR). <i>Journal of Electrocardiology</i> , 2020, 63, 167-172.	0.9	4
31	Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). <i>American Heart Journal</i> , 2020, 220, 246-252.	2.7	74
32	Challenges in Cardiac and Pulmonary Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1878-1901.	2.8	119
33	Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: A systematic review. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1373-1381.	1.2	7
34	Current perspectives on the immunopathogenesis of sarcoidosis. <i>Respiratory Medicine</i> , 2020, 173, 106161.	2.9	19
35	Exploring Occupational, Recreational, and Environmental Associations in Patients With Clinically Manifest Cardiac Sarcoidosis. <i>CJC Open</i> , 2020, 2, 585-591.	1.5	4
36	Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. <i>Journal of the American Heart Association</i> , 2020, 9, e017086.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. <i>Journal of Medical Economics</i> , 2020, 23, 1401-1408.	2.1	1
38	The Clinical Utility of Continuous QT Interval Monitoring in Patients Admitted With COVID-19 Compared With Standard of Care: A Prospective Cohort Study. <i>CJC Open</i> , 2020, 2, 592-598.	1.5	0
39	Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2020, 13, e007405.	3.9	353
40	Treatment with corticosteroids is associated with an increase in ventricular arrhythmia burden in patients with clinically manifest cardiac sarcoidosis: Insights from implantable cardioverter-defibrillator diagnostics. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2751-2758.	1.7	13
41	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 2972-2982.	3.1	9
42	Debating the Definition and Incidence of Isolated Cardiac Sarcoidosis. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1190-1191.	3.2	2
43	Do acute changes in ambient air pollution increase the risk of potentially fatal cardiac arrhythmias in patients with implantable cardioverter defibrillators?. <i>Environmental Health</i> , 2020, 19, 72.	4.0	3
44	Reproducibility of cardiac magnetic resonance imaging in patients referred for the assessment of cardiac sarcoidosis; implications for clinical practice. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2199-2207.	1.5	4
45	Cardiac Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 626-640.	2.1	22
46	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	3.2	15
47	Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. <i>Lancet, The</i> , 2020, 395, 339-349.	13.7	60
48	Serial ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Imaging in a Patient With Giant Cell Myocarditis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009940.	2.6	11
49	Catheter Ablation of Low-Voltage Areas for Persistent Atrial Fibrillation: Procedural Outcomes Using High-Density Voltage Mapping. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1956-1964.	1.7	14
50	High-power short-duration radiofrequency ablation of typical atrial flutter. <i>Heart Rhythm O2</i> , 2020, 1, 317-323.	1.7	5
51	FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET. <i>EJNMMI Research</i> , 2020, 10, 154.	2.5	11
52	Comparing and Contrasting Guidelines for the Management of Cardiac Sarcoidosis. <i>Annals of Nuclear Cardiology</i> , 2020, 6, 61-66.	0.2	1
53	The Role of 18F-FDG PET/CT in Cardiac Sarcoidosis. <i>International Journal of Cardiovascular Sciences</i> , 2020, , .	0.1	1
54	Left atrial imaging and registration of fibrosis with conduction voltages using LGE-MRI and electroanatomical mapping. <i>Computers in Biology and Medicine</i> , 2019, 111, 103341.	7.0	5

#	ARTICLE	IF	CITATIONS
55	To continue or stop oral anti-coagulation in higher-risk patients after a "successful" AF ablation; that is the question. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1258-1260.	1.7	2
56	A Strategy of Lead Abandonment in a Large Cohort of Patients With Sprint-Fidelis Leads. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1059-1067.	3.2	4
57	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007545.	4.8	25
58	Cover Image, Volume 30, Issue 1. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, i.	1.7	0
59	Letter by Birnie et al Regarding Article, "Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis: Implications for the Diagnosis of Isolated Cardiac Sarcoidosis"; <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009614.	2.6	0
60	Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2280-2281.	5.3	30
61	The Final Scene of Act III of the "AF Ablation Story". <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 977-978.	3.2	0
62	Spontaneous coronary artery dissection in cardiac sarcoidosis. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz033.	0.4	6
63	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. <i>International Journal of Cardiology</i> , 2019, 288, 87-93.	1.7	10
64	Adaptive cardiac resynchronization therapy is associated with decreased risk of incident atrial fibrillation compared to standard biventricular pacing: A real-world analysis of 37,450 patients followed by remote monitoring. <i>Heart Rhythm</i> , 2019, 16, 983-989.	0.7	21
65	Adaptive Cardiac Resynchronization Therapy Reduces Atrial Fibrillation Incidence in Heart Failure Patients With Prolonged AV Conduction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007260.	4.8	14
66	Letter to the Editor regarding the paper "Cardioversion of atrial fibrillation in obese patients: Results from the Cardioversion-BMI randomized controlled trial"; <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1762-1763.	1.7	0
67	Improving first shock success in patients with atrial fibrillation undergoing electrical cardioversion: Authors' reply. <i>Europace</i> , 2019, 21, 833-834.	1.7	0
68	Lead-Specific Features Predisposing to the Development of Tricuspid Regurgitation After Endocardial Lead Implantation. <i>CJC Open</i> , 2019, 1, 316-323.	1.5	9
69	Cardiac Sarcoidosis. <i>Current Cardiology Reports</i> , 2019, 21, 152.	2.9	37
70	Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 78-88.	1.7	36
71	Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants. <i>Europace</i> , 2019, 21, 48-53.	1.7	17
72	Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol. <i>Europace</i> , 2019, 21, 708-715.	1.7	19

#	ARTICLE	IF	CITATIONS
73	To continue or minimally interrupt direct oral anticoagulants around ablation for atrial fibrillation: that is the question. <i>Europace</i> , 2019, 21, 531-532.	1.7	1
74	Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. <i>American Heart Journal</i> , 2019, 207, 1-9.	2.7	19
75	Sensitivity and specificity of chest imaging for sarcoidosis screening in patients with cardiac presentations. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 18-24.	0.2	7
76	Mitral valve repair results in suppression of ventricular arrhythmias and normalization of repolarization abnormalities in mitral valve prolapse. <i>HeartRhythm Case Reports</i> , 2018, 4, 191-194.	0.4	11
77	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	4.8	2
78	How common is isolated cardiac sarcoidosis? Extra-cardiac and cardiac findings on clinical examination and whole-body ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>International Journal of Cardiology</i> , 2018, 253, 189-193.	1.7	56
79	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018, 197, 124-132.	2.7	50
80	Characterization of Low-Voltage Areas in Patients With Atrial Fibrillation: Insights From High-Density Intracardiac Mapping. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1033-1040.	1.7	11
81	Association between transthoracic impedance and electrical cardioversion success with biphasic defibrillators: An analysis of 1055 shocks for atrial fibrillation and flutter. <i>Clinical Cardiology</i> , 2018, 41, 666-670.	1.8	13
82	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
83	Which Patients With Cardiac Sarcoidosis Should Receive Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006685.	4.8	13
84	The Impact of Cardiac Rehabilitation on Mental and Physical Health in Patients With Atrial Fibrillation: A Matched Case-Control Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1512-1521.	1.7	11
85	Heart Transplantation for End-Stage Cardiac Sarcoidosis: Increasingly Used With Excellent Results. <i>Canadian Journal of Cardiology</i> , 2018, 34, 956-958.	1.7	7
86	Bi-atrial fibrosis detected using three-dimensional late gadolinium enhancement magnetic resonance imaging in a patient with cardiac sarcoidosis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy016.	0.4	2
87	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
88	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017, 19, euw116.	1.7	20
89	Identifying and Managing Premature Ventricular Contraction-Induced Cardiomyopathy: What, Why, and How?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 287-290.	1.7	5
90	Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation. <i>Circulation</i> , 2017, 135, 1788-1798.	1.6	66

#	ARTICLE	IF	CITATIONS
91	Reply. Journal of the American College of Cardiology, 2017, 69, 363.	2.8	1
92	Inter- and Intraobserver Agreement of ¹⁸ F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis. Journal of Nuclear Medicine, 2017, 58, 1324-1329.	5.0	32
93	Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?. International Journal of Cardiology, 2017, 240, 297-301.	1.7	18
94	A case of pacemaker "malfunction": Should I intervene?. Journal of Electrocardiology, 2017, 50, 939-940.	0.9	1
95	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. Canadian Journal of Cardiology, 2017, 33, 977-990.	1.7	8
96	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	31
97	Risk of Stroke and Recurrence After AF Ablation in Patients With an Initial Event-Free Period of 12 Months. Journal of Cardiovascular Electrophysiology, 2017, 28, 273-279.	1.7	14
98	Reply: Using and Interpreting ¹⁸ F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 2040.1-2040.	5.0	2
99	Bidirectional ventricular tachycardia in ischemic cardiomyopathy during ablation. HeartRhythm Case Reports, 2017, 3, 527-530.	0.4	7
100	Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm, 2017, 14, 1820-1825.	0.7	51
101	Joint SNMMI-ASNC expert consensus document on the role of ¹⁸ F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. Journal of Nuclear Cardiology, 2017, 24, 1741-1758.	2.1	132
102	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. European Journal of Heart Failure, 2017, 19, 950-957.	7.1	33
103	Joint SNMMI-ASNC Expert Consensus Document on the Role of ¹⁸ F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal of Nuclear Medicine, 2017, 58, 1341-1353.	5.0	187
104	Subclinical Atrial Fibrillation in Older Patients. Circulation, 2017, 136, 1276-1283.	1.6	194
105	Efficacy and safety of driver-guided catheter ablation for atrial fibrillation: A systematic review and meta-analysis. Journal of Cardiovascular Electrophysiology, 2017, 28, 1371-1378.	1.7	35
106	Three-year outcomes and reconnection patterns after initial contact force guided pulmonary vein isolation for paroxysmal atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2017, 28, 984-993.	1.7	17
107	Letter by Nery et al Regarding Article, "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis". Circulation, 2017, 135, e1198-e1199.	1.6	1
108	Role of ¹⁸ F-Fluorodeoxyglucose/Positron Emission Tomography Imaging to Demonstrate Resolution of Acute Myocarditis. Canadian Journal of Cardiology, 2017, 33, 293.e3-293.e5.	1.7	4

#	ARTICLE	IF	CITATIONS
109	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	1.7	84
110	Clinical Management of Cardiac Sarcoidosis. <i>Annals of Nuclear Cardiology</i> , 2017, 3, 131-136.	0.2	3
111	Comparing and Contrasting Guidelines for the Diagnosis of Cardiac Sarcoidosis. <i>Annals of Nuclear Cardiology</i> , 2017, 3, 46-47.	0.2	3
112	Radiation safety and ergonomics in the electrophysiology laboratory. <i>Current Opinion in Cardiology</i> , 2016, 31, 11-22.	1.8	11
113	Electrophysiological abnormalities in subjects with lone atrial fibrillation â€œ Too little, too late?. <i>Indian Pacing and Electrophysiology Journal</i> , 2016, 16, 149-151.	0.6	0
114	Relationship Between Pulmonary Vein Reconnection and Atrial Fibrillation Recurrence. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 474-483.	3.2	104
115	Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naïve patients with conduction system disease due to cardiac sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 259-269.	6.4	73
116	Cardiac manifestations of sarcoidosis: diagnosis and management. <i>European Heart Journal</i> , 2016, 38, ehw328.	2.2	77
117	Cardiac Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 411-421.	2.8	400
118	Effect of Applying Force to Self-Adhesive Electrodes on Transthoracic Impedance: Implications for Electrical Cardioversion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1141-1147.	1.2	16
119	Canadian Registry of Implantable Electronic Device Outcomes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	17
120	Late resolution of pacemaker lead-related severe tricuspid regurgitation and right ventricular dysfunction after percutaneous lead extraction: A case report and review of the literature. <i>Heart Rhythm Case Reports</i> , 2016, 2, 324-327.	0.4	1
121	Impact of generator replacement on the risk of Fidelis lead fracture. <i>Heart Rhythm</i> , 2016, 13, 1618-1623.	0.7	3
122	Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. <i>Heart</i> , 2016, 102, 411-414.	2.9	32
123	Outcome of Apparently Unexplained Cardiac Arrest. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003619.	4.8	56
124	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
125	Management of antithrombotic therapy during cardiac implantable device surgery. <i>Journal of Arrhythmia</i> , 2016, 32, 163-169.	1.2	19
126	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.7	34

#	ARTICLE	IF	CITATIONS
127	Advanced Imaging of Cardiac Sarcoidosis. <i>Current Cardiology Reports</i> , 2015, 17, 17.	2.9	14
128	Cost Effectiveness of Continued Warfarin Versus Heparin-Bridging Therapy During Pacemaker and Defibrillator Surgery. <i>Journal of the American College of Cardiology</i> , 2015, 65, 957-959.	2.8	13
129	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 152-158.	4.8	29
130	Meta-Analysis of Continuous Oral Anticoagulants Versus Heparin Bridging in Patients Undergoing CIED Surgery: Reappraisal after the BRUISE Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 417-423.	1.2	36
131	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2015, 17, 1197-1214.	1.7	160
132	Cardiac Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 657-668.	2.1	30
133	Letter by Lewis et al Regarding Article, "REPLACE DARE (Death After Replacement Evaluation) Score: Determinants of All-Cause Mortality After Implantable Device Replacement or Upgrade From the REPLACE Registry"; <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 512-512.	4.8	1
134	Myocardial Injury Secondary to ICD Shocks: Insights from Patients with Lead Fracture. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 237-241.	1.2	21
135	Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 364-374.	1.2	96
136	Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middle-Aged Adults. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 875-881.	1.7	150
137	Development and optimization of SPECT gated blood pool cluster analysis for the prediction of CRT outcome. <i>Medical Physics</i> , 2014, 41, 072506.	3.0	5
138	Decision Making at the Time of ICD Generator Change. <i>JAMA Internal Medicine</i> , 2014, 174, 1508.	5.1	29
139	Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction. <i>Current Opinion in Cardiology</i> , 2014, 29, 152-159.	1.8	6
140	SPECT gated blood pool phase analysis of lateral wall motion for prediction of CRT response. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 559-569.	1.5	10
141	Radiographic Predictors of Lead Conductor Fracture. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1070-1077.	4.8	13
142	Management of Anticoagulation Around Pacemaker and Defibrillator Surgery. <i>Circulation</i> , 2014, 129, 2062-2065.	1.6	24
143	Atrioesophageal Fistula in the Era of Atrial Fibrillation Ablation: A Review. <i>Canadian Journal of Cardiology</i> , 2014, 30, 388-395.	1.7	75
144	Evaluation of Genes Encoding for the Transient Outward Current (Ito) Identifies the <i>KCNQ2</i> Gene as a Cause of J-Wave Syndrome Associated With Sudden Cardiac Death. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 782-789.	5.1	53

#	ARTICLE	IF	CITATIONS
145	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. <i>Heart Rhythm</i> , 2014, 11, 1304-1323.	0.7	1,077
146	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. <i>Canadian Journal of Cardiology</i> , 2014, 30, 231-236.	1.7	35
147	Cardiac Resynchronization Therapy in a Patient with Persistent Left Superior Vena Cava Draining into the Coronary Sinus and Absent Innominate Vein: A Case Report and Review of Literature. <i>Indian Pacing and Electrophysiology Journal</i> , 2014, 14, 268-272.	0.6	4
148	Peri-device Implantation Anticoagulation Management: Evidence and Clinical Implications. , 2014, , 653-664.		0
149	Discerning the Incidence of Symptomatic and Asymptomatic Episodes of Atrial Fibrillation Before and After Catheter Ablation (DISCERN AF). <i>JAMA Internal Medicine</i> , 2013, 173, 149.	5.1	267
150	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	1.7	22
151	Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1034-1041.	1.7	219
152	Clinical outcomes with synchronized left ventricular pacing: Analysis of the adaptive CRT trial. <i>Heart Rhythm</i> , 2013, 10, 1368-1374.	0.7	139
153	Isolated Cardiac Sarcoidosis: Establishing the Diagnosis With Electroanatomic Mapping-Guided Endomyocardial Biopsy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1015.e1-1015.e3.	1.7	63
154	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 368, 2084-2093.	27.0	482
155	Device Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 369, 1570-1572.	27.0	9
156	Impact of QRS Morphology and Duration on Outcomes After Cardiac Resynchronization Therapy. <i>Circulation: Heart Failure</i> , 2013, 6, 1190-1198.	3.9	133
157	Is There an Association Between Clinical Presentation and the Location and Extent of Myocardial Involvement of Cardiac Sarcoidosis as Assessed by ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography?. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 617-626.	2.6	83
158	Clinical Predictors of Fidelis Lead Failure. <i>Circulation</i> , 2012, 125, 1217-1225.	1.6	103
159	The Use of ¹⁸ F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience. <i>Journal of Nuclear Medicine</i> , 2012, 53, 241-248.	5.0	438
160	Cardiac resynchronization therapy. <i>Current Opinion in Cardiology</i> , 2012, 27, 137-142.	1.8	0
161	Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy. <i>Europace</i> , 2012, 14, 690-695.	1.7	33
162	Anticoagulation Bridging Around Device Surgery: Compliance with Guidelines. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 1480-1486.	1.2	9

#	ARTICLE	IF	CITATIONS
163	Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the adaptive CRT trial. <i>Heart Rhythm</i> , 2012, 9, 1807-1814.e1.	0.7	223
164	A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial. <i>American Heart Journal</i> , 2012, 163, 747-752.e1.	2.7	54
165	Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 73-83.	2.1	16
166	Psychological Adjustment in ICD Patients Living With Advisory Fidelis Leads. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 57-63.	1.7	36
167	Prevalence and Risk Factors for Cervical and Lumbar Spondylosis in Interventional Electrophysiologists. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 957-960.	1.7	43
168	Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. <i>Heart</i> , 2011, 97, 2078-2087.	2.9	107
169	Relation Between Right Ventricular Function and Increased Right Ventricular [¹⁸ F]Fluorodeoxyglucose Accumulation in Patients With Heart Failure. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 59-66.	2.6	63
170	Adjusting the timing of left-ventricular pacing using electrocardiogram and device electrograms. <i>Europace</i> , 2011, 13, 1464-1470.	1.7	25
171	SPECT blood pool phase analysis can accurately and reproducibly quantify mechanical dyssynchrony. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 803-810.	2.1	13
172	Predictors of Fracture Risk of a Small Caliber Implantable Cardioverter Defibrillator Lead. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 437-443.	1.2	31
173	Complications Associated With Revision of Sprint Fidelis Leads. <i>Circulation</i> , 2010, 121, 2384-2387.	1.6	88
174	Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 2385-2395.	27.0	1,585
175	Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 774-782.	2.8	222
176	In-hospital mortality in 13,263 survivors of out-of-hospital cardiac arrest in Canada. <i>American Heart Journal</i> , 2010, 159, 577-583.e1.	2.7	14
177	Optimization and validation of radionuclide angiography phase analysis parameters for quantification of mechanical dyssynchrony. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 895-903.	2.1	21
178	Living with an Advisory ICD: How Are the Patients Doing?â€”Actually Just Fine. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1004-1005.	1.2	0
179	Formation of a national network for rapid response to device and lead advisories: The Canadian Heart Rhythm Society Device Advisory Committee. <i>Canadian Journal of Cardiology</i> , 2009, 25, 403-405.	1.7	7
180	Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. <i>Heart Rhythm</i> , 2009, 6, 1276-1279.	0.7	33

#	ARTICLE	IF	CITATIONS
181	Effect of lateral wall scar on reverse remodeling with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2009, 6, 1721-1726.	0.7	32
182	Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: The Canadian Heart Rhythm Society Device Advisory Committee. <i>Heart Rhythm</i> , 2009, 6, 474-477.	0.7	22
183	Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. <i>Current Opinion in Cardiology</i> , 2009, 24, 82-87.	1.8	31
184	Accelerating risk of Fidelis lead fracture. <i>Heart Rhythm</i> , 2008, 5, 1375-1379.	0.7	72
185	Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee. <i>Heart Rhythm</i> , 2008, 5, 639-642.	0.7	79
186	No long-term psychological morbidity living with an implantable cardioverter defibrillator under advisory: the Medtronic Marquis experience. <i>Europace</i> , 2008, 11, 26-30.	1.7	24
187	Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. <i>Cmaj</i> , 2007, 177, 41-46.	2.0	41
188	Transient left ventricular apical ballooning following a prolonged ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2007, 17, 47-49.	1.3	3
189	The problem of non-response to cardiac resynchronization therapy. <i>Current Opinion in Cardiology</i> , 2006, 21, 20-26.	1.8	250
190	Reasons for Escalating Pacemaker Implants. <i>American Journal of Cardiology</i> , 2006, 98, 93-97.	1.6	82
191	Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac death. <i>Europace</i> , 2006, 8, 1054-1056.	1.7	19
192	Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy?. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1763-8.	5.0	24
193	Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. <i>Cmaj</i> , 2004, 171, 1053-1056.	2.0	13
194	Left Atrial Vein Pacing: A Technique of Batrial Pacing for the Prevention of Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2004, 27, 240-245.	1.2	5
195	Atypical Presentation of Cardiac Sarcoidosis and the Role of Multimodality Imaging. <i>Circulation: Cardiovascular Imaging</i> , 0, , .	2.6	0